Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI362 Multiple Subcutaneous Doses in Overweight or Obese Patients
CTR20201033Phase 2Completed
- Sponsor
- Innovent Biologics
- Start
- Jun 2020
- Modality
- Hormonal Peptides → Native Peptides → Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of mazdutide in obesity, Overweight, sponsored by Innovent Biologics. Started Jun 2020; status: completed.
02
Drugs
mazdutide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20201033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201033.